Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From RemeGen Ltd.
Chief medical officer Roger Dansey has stepped in as interim CEO until a new one is appointed.
RemeGen touched down in Shanghai to score a dual listing on top of a 2020 initial public offering in Hong Kong. Meanwhile, domestic HPV vaccine maker Recbio and small molecule-focused Shouyao made their debuts on the Hong Kong and Shanghai markets respectively.
Out of the more than 40 approvals granted to new drugs in China in 2021, domestic companies bagged around half to catch up with their multinational peers in the annual innovation scorecard.
Latest option deal with Swiss major solidifies BeiGene’s front-runner position in PD-1 combination therapy with novel antibodies.
- Large Molecule